ProCE Banner Activity

Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Slideset Download
Download these slides from an expert-led symposium reviewing updates in oral targeted therapy for HR-positive/HER2-negative breast cancer and implementation in clinical practice.

Released: March 30, 2022

Expiration: March 29, 2023

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Kristina F. Byers

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca and BeyondSpring.

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Kristina F. Byers, PharmD, BCOP, has disclosed that she has received consulting fees from Seagen and has been a speaker for Wellstat Therapeutics.